Arpida Presents Preclinical and Clinical Data on Iclapri...(ty against severalclones of MRSA (E-MRSA...)

B-817: A novel staphylococcal murine preclinical model of infection was established for diaminopyrimidines. The efficacy of iclaprim was shown to be equal or better than that of vancomycin.

E-903, E-907, E-908, E-909: Iclaprim shows good activity against important pathogens such as Chlamydia trachomatis, Legionella pneumophila, Neisseria gonorrhoeae and Enterobacteriaceae. These are involved in various clinical indications.

A-804, A-805, A-806: Important Phase I data on intravenous and oral iclaprim. Iclaprim exhibited extensive tissue distribution, showed good oral bioavailability and was well-tolerated in volunteers.

A-803, A-807: these posters described important data on pharmacokinetics in the marmoset and in vitro interaction studies with CYP450 enzymes.

D-243, D-244, D-245: These posters describe the reliability of results when testing susceptibility for iclaprim using various methods and under different circumstances. The studies show a narrow range of test results and a good correlation between Minimum Inhibitory Concentrations (MICs) under different methods.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance.

Arpida's leading product candidate is intravenous iclaprim, a broad-spectrum antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In July 2007, Arpida reported the completion of the Phase III programme in complicated skin and skin
'/>"/>